Study Evaluating the Safety of HCV-796 in Subjects With Liver Disease and in Healthy Adults

An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of HCV-796 in Subjects With Chronic Hepatic Impairment and in Matched Healthy Adults

The purpose of this study is to assess the pharmacokinetics (PK) of HCV-796 in subjects with chronic hepatic impairment and in matched healthy adults.

Inclusion Criteria:

• Men and women of non-childbearing potential.
• Hepatic impairment subjects: Child-Pugh class A, B, or C according to the C-P classification based on history, physical examination, and laboratory test results.
• Healthy volunteers: healthy as determined by the investigator.

Exclusion Criteria:

• History of alcoholism within 1 year.
• Hepatic impairment subjects: evidence of unstable clinically significant disease other than impaired hepatic function.
• Healthy volunteers: positive serologic findings for hepatitis B surface antigen (HBsAg) and/or hepatitis C virus (HCV) antibodies.